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Porcine hepatocytes transplanted during acute liver failure might support metabolic functions until the diseased liver recovers its
function. Here, we isolated high numbers of viable pig hepatocytes and evaluated hepatocyte functionality after encapsulation. We
further investigated whether coculture and coencapsulation of hepatocytes with human multipotent mesenchymal stromal cells
(MSC) are beneﬁcial on hepatocyte function. Livers from 10 kg pigs (n = 9) were harvested, and hepatocytes were isolated from
liver suspensions for microencapsulation using alginate and poly(ethylene-glycol)- (PEG-) grafted alginate hydrogels, either
alone or in combination with MSC. Viability, albumin secretion, and diazepam catabolism of hepatocytes were measured for
one week. 9.2± 3.6× 109 hepatocytes with 95.2± 3.1% viability were obtained after isolation. At day 3, free hepatocytes displayed
99% viability, whereas microencapsulation in alginate and PEG-grafted alginate decreased viability to 62% and 48%,
respectively. Albumin secretion and diazepam catabolism occurred in free and microencapsulated hepatocytes. Coencapsulation
of hepatocytes with MSC signiﬁcantly improved viability and albumin secretion at days 4 and 8 (p < 0 05). Coculture with MSC
signiﬁcantly increased and prolonged albumin secretion. In conclusion, we established a protocol for isolation and
microencapsulation of high numbers of viable pig hepatocytes and demonstrated that the presence of MSC is beneﬁcial for the
viability and function of porcine hepatocytes.
1. Introduction
Hepatocyte cell transplantation is a potential solution to
temporarily improve acute liver failure in patients that are
waiting for a liver transplant [1]. Nevertheless, for patients
with acute liver failure, the availability of suitable human
liver cells remains a major problem. Transplantation of
xenogeneic cells could be an adequate cell replacement treat-
ment [2]. To circumvent the immune reaction toward the
xenogeneic cells, encapsulation of cells in a semipermeable
biocompatible polymer has been developed [3]. Micropores
permit exchanges of nutrients, oxygen, and small-sized mol-
ecules. The promising ﬁrst transplants with encapsulated
hepatocytes in pig-to-rodent animal models showed that
such transplanted encapsulated hepatocytes were still func-
tional over several weeks [4–6]. In a pig-to-baboon model,
75% of baboons after induction of fulminant liver failure
and subsequent transplantation with encapsulated hepato-
cytes recovered from liver injury [7], demonstrating further
the therapeutic potential of such a treatment.
Previously, our laboratory established the ﬁrst protocol
for the isolation of primary pig and human hepatocytes and
their encapsulation with alginate- (Alg-) poly-L-lysine (PLL)
polymers [5, 6]. However, hepatocytes when encapsulated
showed reduced functionality suggesting that polymers and
microenvironmental conditions needed further optimization.
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Indeed, neonatal pig hepatocytes showed increased viability
and functionality when previously reaggregated [4] or when
heparin or hepatocyte growth factor was added during the
encapsulation procedure [8]. The addition of PLL and colla-
gen during encapsulation in alginate microcapsules pro-
longed viability and functionality, as demonstrated for cells
of the human hepatocellular carcinoma cell line HepG2/
C3A [9]. Further, coculture or coencapsulation with other cell
types such as endothelial progenitor cells or ﬁbroblasts
showed enhanced viability and function of rat hepatocytes
[10, 11].
Multipotent mesenchymal stromal cells, also called mes-
enchymal stem cells (MSC), support the growth of rodent
hepatocytes by favoring cellular adhesion in vitro [12, 13]
and in vivo [14]. Several studies in rodents have shown that
cotransplantation of free primary hepatocytes with rat MSC
prolonged graft function with a decrease in alanine transam-
inase (ALT), aspartate transaminase (AST), and bilirubin
[15–17]. Further, coculture of rodent hepatocytes with MSC
improved albumin secretion and metabolic capacities of
hepatocytes [15, 16, 18].
The aim of this study was to optimize hepatocyte isola-
tion to reach high yields of viable porcine hepatocytes and
to assess viability, albumin secretory capacities, and meta-
bolic functions after in vitro culture and microencapsulation.
Furthermore, we aimed to assess the eﬀect of humanMSC on
free and coencapsulated porcine hepatocytes, with particular
attention to the eﬀect on viability, albumin secretion, and cell
morphology of pig hepatocytes.
2. Materials and Methods
2.1. Animals and Liver Harvesting. Ten-kilogram pigs were
purchased from a local pig farm (M. Stirnimann, Apples,
Switzerland) and were shortly housed in the animal facility
of the University of Geneva, in compliance with all cantonal
dispositions. Animal research was performed following
protocols approved by the Geneva cantonal veterinary
authorities (license GE/79/15). Pigs were fasted overnight
and premedicated with azaperone (1mg/kg) and atropine
(0.05mg/kg) +dormicum (0.5mg/kg) by intramuscular
injection, prior to anesthesia with isoﬂurane, fentanyl
(0.1mg), and atracurium (1mg/kg). After heparin injection
(5000 U/L) and disinfection, an abdominal incision was per-
formed, followed by gallbladder removal and perfusion with
cold preservation medium IGL-1 (3.5 L) (Institut Georges
Lopez, Lissieu, France) through the portal vein and the
hepatic artery. A total hepatectomy was performed, and the
liver was stored on ice for a maximum of 30min prior to
hepatocyte isolation.
2.2. Cell Isolation and Culture. Isolation of porcine hepato-
cytes was performed as previously described [5]. Brieﬂy, the
liver was perfused through the vena cava with liver perfusion
medium for 15 minutes at 37°C (Life Technologies, Carlsbad,
CA, USA); thereafter, digestion media containing collagenase
NB 4 Standard Grade (3 g/L; Serva, Heidelberg, Germany)
were infused for 25 minutes through the vena cava
(Figure 1). Mechanical destruction and ﬁltration of the liver
through a 100μm stainless steel mesh were performed to
obtain a hepatocyte suspension, as previously described [5].
The hepatocyte cell suspension was washed twice using hepa-
tocyte wash medium (Life Technologies) and centrifuged at
68g for 10 minutes; cells were counted and then cultured in
DMEM/F12 (Life Technologies), supplemented with dexa-
methasone (0.4μg/mL, Sigma-Aldrich, Buchs, Switzerland),
insulin (0.02 E/U/mL, Novo Nordisk, Plainsboro, NJ, USA),
apo-transferrin (5μg/mL, Sigma), penicillin (100 IU/mL)
and streptomycin (100mg/mL) (P-S; Gibco-Thermo Fisher,
Waltham, MA, USA), and 10% of autologous serum,
Solution collector
Organ
Perfusion
media
Digestion
media
Water bath
Pump
O2
Figure 1: Liver perfusion and digestion system. The isolated liver is maintained at 37°C by water circulation (in blue) supplied by a water bath
kept at 37°C. Perfusion and digestion media are maintained at 37°C and oxygenated through the oxygen cylinder (in green). Thereafter,
infusion of perfusion media followed by digestion media (in red) into the liver is performed via the vena cava. Flow-through of both
media (in brown) is recovered and discarded.
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obtained after clotting and high-speed centrifugation of por-
cine blood.
MSC were isolated from the femoral head of the patients
undergoing total hip replacement. MSC were characterized
by surface receptor expression using FACS analysis and by
their capacity to diﬀerentiate into osteoblasts, chondrocytes,
and adipocytes as shown previously [19, 20]. All patients
gave informed consent, and the experimental procedure
was approved by the local ethical committee of the Univer-
sity Hospitals of Geneva (NAC 01-015). Brieﬂy, after isola-
tion, through mechanical destruction and Ficoll density
gradient centrifugation, MSC were cultured in Iscove’s
modiﬁed Dulbecco’s medium (Gibco-Thermo Fisher) with
10% fetal calf serum (Gibco-Thermo Fisher), P-S, and
10ng/mL platelet-derived growth factor BB (PDGF-BB;
PeproTech EC Ltd., London, UK). MSC were used from
passages 2 to 5.
2.3. Polymer Synthesis. Sodium-Alg Kelton High Viscosity
(lot number 61650A; η=813mL·g−1 in 0.1M NaCl, T =
25°C, and G/M=0.6) was obtained from Kelco (San Diego,
CA, USA). Commercial reagents (Fluka, Sigma, Switzerland;
TCI Europe, Zwijndrecht, Belgium) were used without fur-
ther puriﬁcation. Unless mentioned otherwise, all reactions
were performed under argon atmosphere (1 atm). Anhy-
drous solvents were obtained by ﬁltration (PureSolv MD
5, Innovative Technology, Oldham, UK). Glassware was
dried for 12 h in an oven (T> 100°C) or under vacuum
with a heat gun (T> 200°C). Nuclear magnetic resonance
(NMR) spectra were recorded on Bruker Avance III-400,
Bruker Avance-400, or Bruker DRX-400 spectrometers at
room temperature (rt) (400MHz) (Bruker, Billerica, MA,
USA). 1H frequency is at 400.13MHz. Chemical shifts are
expressed in parts per million (ppm) and coupling con-
stants (J) in hertz (Hz). The solvent used for NMR spec-
troscopy was deuterated water.
Polymer Alg-poly(ethylene-glycol)- (PEG-) SH (Alg-
PEG-SH) was prepared according to a procedure that we
recently established [21]. A solution of thiobarbituric acid-
(TBA-) Alg [22] (200mg, 0.478mmol) in dimethyl sulfoxide
(DMSO) (40mL)was stirred for 12hours at 22°C.To this solu-
tion, 1,1′-carbonyldiimidazole (CDI) (77.4mg, 0.478mmol)
was added, and the mixture was stirred at 22°C for 0.5 h. Ace-
tone (80mL) was added, and the resulting precipitate was ﬁl-
tered and washed with acetone (20mL, 3 times). The solid
was dried for 15minutes under vacuum at 40°C and dissolved
in distilled water (20mL). A solution of α-amino-ω-azido
PEG (H2N-PEG-SH) (98.8mg, 95.8μmol) in distilled water
(1mL) was added, and the solution was stirred for 2 hours
at 22°C. NaOH (0.05M aqueous solution) was added
until reaching pH11.0, and the solution was transferred
to a dialysis membrane and dialyzed against water. After
one water change, tris(2-carboxyethyl)phosphine (TCEP)
(0.1M, 1mL) was added in the dialysis tube, and the dialysis
was continued against water for 3 days. An aqueous solution
of NaHCO3 was added until reaching pH7. The solution was
ﬁltered (70μm and 0.22μm) and freeze-dried to aﬀord Alg-
PEG-SH as a white solid (106.7mg) (Supplementary Figure
1). The percentage of grafting, determined by H-NMR, was
30.3%. The viscosity of the polymer (measured in distilled
water at 22°C) was 204.6mPa·s.
2.4. Hepatocyte Microencapsulation. Hepatocytes and MSC
were coencapsulated in a ratio 1 : 1, keeping in mind that
hepatocytes are in contact with nonparenchymal cells in liver
plates [23]. Hepatocytes (3× 106/mL of polymer) with or
without MSC (3× 106/mL of polymer) were gently mixed
with calcium-alginate (Ca-Alg), under sterile conditions.
Alg-PEG-SH (3% diluted in 3-(N-morpholino)propanesulfo-
nic acid (MOPS)) was also used to encapsulate hepatocytes.
All polymers were prepared by collaborators of the École
Polytechnique Fédérale de Lausanne. Microbeads were pro-
duced using the Buchi Encapsulator B-395 Pro (Büchi
Labortechnik AG, Flawil, Switzerland). Ionic and covalent
cross-linking occurred immediately after bead immersion
into the gelation bath, composed of 10mM MOPS with
pH=7.4 and 100mM CaCl2. After formation, microspheres
were straightaway collected by ﬁltration to remove the gela-
tion bath, washed with 0.9% NaCl, and immediately cultured
in complete DMEM/F12 medium. The diameter of resulting
beads was 500–600μm for Ca-Alg and 400–500μm for Alg-
PEG-SH [21].
2.5. Viability of Primary and Encapsulated Cells.Viability and
cell death of free and microencapsulated cells (0.2× 106 cells/
1mL/24-well plate) were analyzed using ﬂuorescein diacetate
(FDA) and propidium iodide (PI) for the staining of viable
and dead cells, respectively, as previously described [24].
Images were acquired using a ﬂuorescent microscope and
LAS V4.5 software (Leica Microsystem, Heerbrugg, Switzer-
land). Quantiﬁcation of cell viability was performed 3 days
after culture using ImageJ (https://imagej.nih.gov/ij) and
expressed as a percentage where the sum of the value mea-
sured, for FDA-positive and PI-positive cells in the ﬁeld of
view, was set as 100%.
2.6. Measurement of Albumin Secretion. Hepatocytes
(0.2× 106 cells) alone or with MSC (0.2× 106 cells, ratio
1 : 1) and microencapsulated or not were seeded with 1mL
complete DMEM/F12medium in a 24-well Corning Primaria
Cell Culture Multiwell Plate (Fisher Scientiﬁc, Hampton,
NH, USA). Prior to albumin secretion assays, cells were
washed and serum-starved overnight to remove pig albumin.
Every 24 hours, medium was collected from day 2 to day 8;
samples were frozen until albumin measurements. Albumin
was measured following the manufacturer’s instructions
using an albumin pig ELISA kit (Abcam, Cambridge, UK).
2.7. Measurements of Drug Metabolism. 1μg/mL of diazepam
was added to free and encapsulated hepatocytes (0.2× 106
cells/1mL/24-well plate) for 6 hours at days 1, 3, and 7.
Supernatants were collected and frozen until metabolite mea-
surements. Prior to the quantitative analysis, protein precip-
itation was performed on the samples using a solution of
methanol : ethanol at a ratio 1 : 1. Then, samples were centri-
fuged at 14,000g for 15 minutes. Samples were lyophilized
with a SpeedVac system and reconstituted in 10% methanol.
Quantitative analysis was performed by LC-MS/MS with a
selected reaction monitoring (SRM) mode. The UltiMate
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3000 LC system from Dionex coupled to a triple quadripole
5500 QTRAP system from AB Sciex was used. The LC sepa-
ration was conducted on a Kinetex C18 column (50× 2.1mm
(i.d.)) (Phenomenex). The mobile phases were made of A
(H2O with 0.1% formic acid) and B (ACN+0.1% formic
acid). The ﬂow rate was 0.6mL/min. The SRM transitions
used for the quantiﬁcation of the diazepam and its respective
metabolites are referred in Supplementary Table 1.
2.8. Immunoﬂuorescence Staining on Cultured Cells. Hepato-
cytes (0.2× 106 cells) alone or with MSC (0.2× 106 cells, ratio
1 : 1) were seeded on 12mm coverslips in a 24-well plate in
1mL of complete F12 medium. After 3 days, cells were
washed with phosphate-buﬀered saline (PBS) and ﬁxed with
a 10% formalin solution (Sigma-Aldrich, Buchs, Switzerland)
for 12min. Cells were then permeabilized with Triton X-100
0.1% diluted in PBS for 15min, and epitopes were blocked
using 0.5% bovine serum albumin (BSA) for 30min. Hepato-
cytes were stained with an anti-pig albumin antibody
(Abcam) diluted to 1/200 and a secondary Alexa Fluor 555
goat anti-rabbit antibody (Life Technologies) diluted to 1/
500. MSC were stained with a mouse anti-human vimentin
antibody diluted to 1 : 50 (Dako, Glostrup, Denmark) and a
secondary Alexa Fluor 488 goat anti-mouse antibody (Life
Technologies). For 5-ethynyl-2′-deoxyuridine (Edu) staining,
the Click-iT EdU Alexa Fluor 488 Imaging Kit (Thermo
Fisher) was used following the manufacturer’s instructions.
Coverslips were mounted using VECTASHIELD mounting
mediumwith 4′,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Cambridgeshire, UK). Images were acquired
using aﬂuorescencemicroscope andLASV4.5 software (Leica
Microsystems).
2.9. Measurements of Cytokines in Cell Culture Supernatants.
MSC alone or with hepatocytes (0.2× 106 cells/1mL/24-well
plate) from 2 diﬀerent donors were cultured in complete
hepatocyte medium for 2 days. Cells were washed and cul-
tured for 24 h in medium without FCS. Cell culture superna-
tants were collected and frozen until cytokine measurements.
Cytokines were screened using Proteome Proﬁler, Human
Cytokine Array (R&D Systems, Bio-techne, Minneapolis,
MN, USA), following the manufacturer’s procedures. Quan-
tiﬁcation of cytokine measurements was performed using
ImageJ (https://imagej.nih.gov/ij) and expressed as mean
pixel density.
2.10. Statistical Analysis. Results are expressed as mean±
standard error of the mean (SEM). Numbers of experiments
are indicated in the legend of each ﬁgure. GraphPad Prism
software was used. Values of hepatocytes alone or cocultured
with MSC were compared using the ratio paired t-test,
and diﬀerences were considered signiﬁcant when p < 0 05
∗ , p < 0 01 ∗∗ , and p < 0 001 ∗∗∗ .
3. Results
3.1. Hepatocyte Isolation and Cell Yield and Viability. After
surgical recovery of the livers from 10-kilogram pigs (n = 12),
9.2± 3.6× 109 total hepatocytes were isolated with a yield of
27.9± 9.9× 106 cells/g (Table 1). Immediately after hepato-
cyte isolation and puriﬁcation, viability was of 95.2± 3.1%,
showing that the harvesting protocol allowed the isolation
of high yields of viable porcine hepatocytes from 10-
kilogram pigs. For the ultimate purpose to use frozen-
stored porcine hepatocytes for transplantation, several
batches of hepatocytes (10× 106 hepatocytes in 1mL of cryo-
preservation media) were frozen in 10% DMSO and ready-
to-use CryoStor CS10 (Sigma-Aldrich) cryopreservation
media. CryoStor-frozen cells were thawed in complete
medium. After cell centrifugation at 68g, pellets of cells were
resuspended in complete media. Cells were stained with try-
pan blue, and viability was evaluated under bright-ﬁeld
microscopy. 0.9× 106 hepatocytes were obtained, corre-
sponding to 90% of total cells. After seeding and culture,
hepatocytes maintained viability at 3 days (Figure 2(a)); how-
ever, no viable hepatocytes were recovered when frozen with
DMSO-containing medium. Furthermore, thawed hepato-
cytes after freezing in CryoStor maintained albumin secre-
tion at days 4, 8, and 11 (Figure 2(b)).
3.2. Hepatocyte Viability Is Maintained after Ca-Alg and Alg-
PEG-SH Microencapsulation. During the in vitro culture of
free and encapsulated hepatocytes, we assessed hepatocyte
viability and mortality, using FDA-PI staining each day. In
vitro, free hepatocytes maintained viability up to 10 days in
adherent culture conditions; Alg- and Alg-PEG-SH-micro-
encapsulated hepatocytes remained viable up to 7 days.
After 3 days of culture, free hepatocytes were 99% viable
with minimal cell death (1%; Figures 3(a) and 3(b)). After
microencapsulation in beads of 400–600μm diameters,
Alg-microencapsulated hepatocytes maintained 62% viabil-
ity and Alg-PEG-SH-encapsulated hepatocytes maintained
56% viability (Figures 3(a) and 3(b)). These results demon-
strate that microencapsulation of porcine hepatocytes with
both types of polymers allows survival of up to 50% of the
microencapsulated pig hepatocytes.
3.3. Albumin Secretion Is Maintained in Hepatocytes after
Microencapsulation. To assess hepatocyte functionality after
microencapsulation, albumin secretion was measured start-
ing from day 2 to day 8 in free, Alg-microencapsulated, and
Alg-PEG-SH-microencapsulated hepatocytes.Measurements
at 24 hours showed that free hepatocytes secreted 10–12μg/
mL/24 hours albumin until day 6, and at days 7 and 8, albu-
min secretion was halved (Figure 4(a)). The total amount of
albumin secreted during 8 days was around 46μg/mL in free
cultured hepatocytes (Figure 4(a), grey bar). The albumin
secretion from free hepatocytes isolated from 9 livers was at
similar levels. Alg-microencapsulated hepatocytes secreted
lower amounts of albumin (2–1.5μg/mL/24 h), with a maxi-
mum amount measured at day 4 to day 6. Despite the
Table 1: Hepatocyte isolation.
Total number of hepatocytes 9.2± 3.6× 109
Cells/g 27.9± 9.9× 106
Viability 95.2± 3.1
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decrease in the amount of albumin measured, secretion still
persisted until day 8 (Figure 4(b)). Alg-PEG-SH-microen-
capsulated hepatocytes secreted albumin until day 8 in sim-
ilar amounts when compared with free cultured hepatocytes
(Figure 4(c)), with the highest secretion at day 6. These
results show that microencapsulated hepatocytes secrete
albumin, which is maintained up to 8 days in free, Alg-
microencapsulated, and Alg-PEG-SH-microencapsulated
hepatocytes.
3.4. Microencapsulated Hepatocytes Still Display the Capacity
to Metabolize Diazepam. To evaluate the metabolic capacities
of free and microencapsulated hepatocytes, diazepam was
added at days 1, 3, and 7 to hepatocytes for 6 hours and the
metabolites nordiazepam and temazepam were measured.
As shown in Figure 5, diazepam decreased similarly in both
free and Alg-microencapsulated hepatocytes (white bars).
At day 1, metabolic capacities were maximal; nordiazepam
and temazepam were 49 ng/mL and 93.4 ng/mL, respectively,
in free hepatocytes and 3.5 ng/mL and 5.6 ng/mL, respec-
tively, in microencapsulated hepatocytes. The amounts of
metabolites released decreased progressively between day 3
and 7, for both free and Alg-microencapsulated cells. This
result suggests that, although lower amounts of diazepam
metabolites were measured in the supernatant of encapsu-
lated hepatocytes, hepatic metabolic function for diazepam
still occurred in microencapsulated hepatocytes during the
ﬁrst week of in vitro culture.
3.5. Hepatocytes Show Increased Viability and Albumin
Secretion When Coencapsulated with MSC. Trophic mole-
cules secreted by MSC have been described to be beneﬁcial
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Figure 2: Hepatocyte viability and function after freezing and thawing. (a) The upper panel presents the bright-ﬁeld image of thawed
hepatocytes in culture after 3 days, the middle panel presents viable cells (FDA staining), and the lower panel presents nonviable cells (PI
staining). (b) Albumin was measured by ELISA in the supernatant of cultured hepatocytes at days 4, 8, and 11. The experiment is
performed in duplicates.
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for cell function in acute liver failure [25]. To assess whether
MSC could provide a beneﬁcial eﬀect on microencapsulated
hepatocytes, both were coencapsulated in an Alg micro-
sphere. To assess viability, FDA-PI staining was performed
at day 3. We observed that in capsules containing hepato-
cytes and MSC, total cell death was decreased considering
the total number of PI- and FDA-stained cells. Hepatocyte
survival reached 90% whereas hepatocytes alone reached
40% (Figures 6(a) and 6(b)). Further, to assess the function-
ality of hepatocytes coencapsulated with MSC, albumin
secretion was measured each day starting at day 2 until day
8. In the presence of MSC (grey bars), albumin secretion
was signiﬁcantly higher at days 4, 5, and 8 (p < 0 05,
Figure 7(a)) for hepatocytes coencapsulated with MSC than
for microencapsulated hepatocytes alone (white bars). To
assess the importance of cellular contact between hepatocytes
and MSC, coculture was performed and albumin secretion
was measured in the supernatants. At days 3 and 4, albumin
secretion was signiﬁcantly higher in hepatocytes with the
presence of MSC (grey bars, p < 0 001) compared to hepato-
cytes alone (Figure 7(b), white bars). Noteworthy, MSC alone
secreted only limited amounts of albumin (grey bars).
Further, the presence of MSC allowed prolonging albumin
secretion up to day 15 (Supplementary Figure 2). Diazepam
metabolism of hepatocytes cocultured with MSC was simi-
lar to that of hepatocytes cultured alone (Supplementary
Figure 3), suggesting that the cell-cell contact between
hepatocytes and MSC does not aﬀect metabolic function
of hepatocytes at short time. All together, these results show
that coencapsulation of hepatocytes with MSC improves
and prolongs signiﬁcantly albumin secretion from porcine
hepatocytes.
3.6. Human MSC and Pig Hepatocyte Distribution in
Coculture. Coculture of hepatocytes and MSC was used to
analyze the cell distribution after 3 days of culture. MSC were
stained for the cytoskeleton protein vimentin (in green) and
hepatocytes for albumin (in red) (Figure 8(a)). Hepatocytes
alone formed a typical adherent epithelial cell layer
(Figure 8(a)). In coculture with MSC, hepatocytes appeared
in small cell clusters (hepatocyte doublets or triplets), with
the presence of MSC intermingled throughout the hepatocyte
culture (Figures 8(b) and 8(c)).
3.7. Cytokine Screening in Supernatants of Human MSC
Cultured Alone or with Porcine Hepatocytes. Cytokines
secreted from MSC alone or cocultured with hepatocytes
were screened using a human antibody array to evaluate an
eventual cytokine response from MSC induced by hepato-
cytes. Several cytokines were detected in the 24 h superna-
tants (Figure 9(a)). CCL2, CXCL12, and macrophage
migration inhibitory factor (MIF) were present in both cell
culture supernatants. CXCL1 and IL-8 were only detectable
in the supernatant of MSC from 1 of 2 donors. Interestingly,
serpin E1 was present in the supernatants of MSC cultured
alone, but its presence was signiﬁcantly increased in MSC
cocultured with hepatocytes (Figure 9(b)). These results
show that MSC secrete only few inﬂammatory cytokines
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Figure 3: Viability of free and microencapsulated hepatocytes. (a) Representative images at day 3 for free, Alg-microencapsulated, and Alg-
PEG-SH-microencapsulated hepatocytes. Upper panels present bright-ﬁeld images, middle panels present viable cells (FDA staining), and
lower panels present nonviable cells (PI staining). (b) Quantiﬁcation of viable cells (FDA) and nonviable cells (PI) at day 3. Values are
expressed as % of the total cell area (n = 6). Quantiﬁcation has been performed using ImageJ.
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Figure 4: Albumin secretion from free andmicroencapsulated hepatocytes. Albuminwasmeasured by ELISA in the supernatant of free (n = 9)
(a), alginate-encapsulated (n = 3) (b), and Alg-PEG-SH-encapsulated (n = 3) (c) hepatocytes. White bars represent albumin secretion during
24 h from day 2 to day 8, and grey bars represent the total albumin secreted during 8 days.
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and this also occurs during coculture with porcine hepato-
cytes suggesting further that MSC do not increase the expres-
sion of proinﬂammatory cytokines when in contact with
porcine hepatocytes at a short term.
4. Discussion
Acute liver failure has high mortality rate. Liver transplanta-
tion, which has to occur in the few days following liver
destruction, remains the only treatment with lifelong immu-
nosuppression thereafter [1]. Additionally, the availability of
an adequate human liver is not guaranteed, demonstrating
the need for new therapeutic options. Porcine hepatocyte cell
transplantation might present an alternative solution to over-
come acute liver failure damages by replacing the metabolic
function of the liver until its recovery. Earlier studies in mice
with acetaminophen- and hepatectomy-induced fulminant
liver failure showed that transplantation of microencapsu-
lated human or porcine hepatocytes increased survival rates
of mice [5, 6] and the ﬁrst protocols for porcine hepatocyte
isolation and encapsulation with Alg-PLL capsules were
applied [5, 6].
Here, we developed an optimized high-yield porcine
hepatocyte isolation protocol from 10-kilogram pigs.
Hepatocytes were encapsulated in recently developed bio-
materials which showed an improved biocompatibility,
compared to previous polymers. Currently, new biocompat-
ible biomaterials which allow the production of long-term
stable microspheres for hepatocyte encapsulation are under
investigation. Long-term stability remains an important
issue to prevent immunoreaction due to microcapsule disag-
gregation. Several types of polymers are under investigation.
Durkut and collaborators showed that rat hepatocytes main-
tained comparable viability in free and encapsulated condi-
tions in Alg-chitosan-Alg microcapsules [26]. However, this
study did not focus on microbead stability. Furthermore,
another study reports that hepatocytes isolated from rats
and encapsulated in PEG did not survive after encapsulation
[11]. Therefore, improvements are needed to maintain via-
bility of primary hepatocytes which are highly sensitive to
environmental conditions. Our data shows that using Alg
and a hybrid Alg-PEG-SH biomaterial for encapsulation
allows maintaining 56% viability of encapsulated hepato-
cytes, compared to hepatocytes alone. The diminished hepa-
tocyte viability was reﬂected by decreased albumin secretion
and metabolic activity of diazepam, but the function was
partially maintained after microencapsulation when com-
pared to that of free cultured hepatocytes. Actually, the ini-
tial amount of diazepam decreased in free and encapsulated
conditions; however, the quantity of metabolites did not sig-
niﬁcantly increase in the supernatants of encapsulated hepa-
tocytes. An issue to be considered is that molecule diﬀusion
might be delayed; indeed, albumin and diazepam and its
metabolites may remain longer inside the microsphere,
making it diﬃcult to compare the amounts of molecules
released after 6 hours from free and encapsulated hepa-
tocytes; however, cell viability and molecule dispersion
were maintained.
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Figure 6: Viability of coencapsulated hepatocytes and MSC. (a) Representative images of Alg-encapsulated hepatocytes alone or with MSC
after 4 days of culture. Upper panels present bright-ﬁeld images, middle panels present viable cells (FDA staining), and lower panels present
nonviable cells (PI staining). (b) Quantiﬁcation at day 3. Values are expressed as % of the total cell area (n = 2). Quantiﬁcation has been
performed using ImageJ.
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A number of options to improve hepatocyte viability and
function have been proposed. The supplementationwithmod-
ulators like heparin or collagen during microencapsulation
improves albumin and urea synthesis and increases hepatocyte
viability [8, 9]. For rat hepatocytes, coencapsulation with
other cells such as endothelial progenitor cells improves
albumin and urea secretion [10]. MSC express low levels of
human leukocyte antigen classes 1 and 2 and costimulatory
molecules on their surface, conferring MSC low immunoge-
nicity [27]. Furthermore, MSC have the capacity to suppress
cell activation and proliferation of immune cells, in particular
T cells, B cells, and dendritic cells [28]. The immune response
of MSC to xenogeneic hepatocytes was analyzed using an
antibody array for screening human cytokines. Under our
culture conditions, with two diﬀerent donor-derived MSC
populations, we detected mainly 2 types of cytokines, CCL2
and MIF. CCL-2 and MIF are implicated in the chemotactic
activity of immune cells and cell-mediated immunity,
respectively [29, 30]. Furthermore, serpin E1 is increasingly
detected in coculture conditions with hepatocytes. Serpin
E1 is a serine protease inhibitor [31] secreted by MSC
as demonstrated by Daltro et al., where serpin E1 secreted
by MSC was involved in recovery of cardiac disturbances
[32]. We did not observe major changes in the cytokine
proﬁle of MSC which further suggests that MSC, when
exposed to xenogeneic hepatocytes, do not display a
higher immunogenicity.
Moreover, MSC have antiﬁbrotic properties [20] and
have been successfully used to treat liver failure [33]. There-
fore, we explored the eﬀect of human MSC on porcine
hepatocyte survival and function. The present results show
that MSC signiﬁcantly improve hepatocyte viability and
albumin secretion in coculture and coencapsulated condi-
tions. However, others have reported that for 3D cultures
of human MSC and human hepatocytes, there was no eﬀect
on albumin secretion, but rather hepatocyte was compacted
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Figure 7: Albumin secretion of hepatocytes coencapsulated and cocultured with MSC. Albumin secretion was measured by ELISA in the
supernatant of cell culture after 24 hours from day 2 to day 8. (a) Alg-microencapsulated hepatocytes alone (white bars) or with MSC
(grey bars), measured in 2 independent experiments. (b) Free hepatocytes alone (white bars) or with MSC (grey bars), measured in 5
independent experiments. ∗p < 0 05, ∗∗∗p < 0 001.
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in morphology and there was a phenotypic stability [34].
Also, human MSC potentiated hepatotrophic and antiapop-
totic genes in human primary hepatocytes [35], with the
accumulation of hepatocytes in the G2/S phase of the cell
cycle, meaning that they are prone to proliferation [18]. In
line with these results, in the present study, hepatocytes in
coculture with MSC tend to show extended survival com-
pared to microencapsulated hepatocyte alone.
The mechanism how MSC exert their beneﬁcial eﬀects
needs further investigations and might not solely be due to
paracrine eﬀects. Interestingly, the systemic injection of
extracellular vesicles, derived from bone marrow MSC after
in vitro culture, reduced hepatic injury and improved mice
survival [25], suggesting that such vesicles contain molecules
either acting directly on liver cells or modulating the immune
system. Moreover, the evaluation of the secretome of human
MSC evidenced a correlation between vascular endothelial
growth factor and cell proliferation, development processes,
and immune processes. Also, systemic injection of condi-
tioned medium of MSC in liver-injured mice improved
survival [36]. In our experimental conditions, we found
increased albumin secretion when hepatocyte and MSC were
cultured together; this might not be due exclusively to cellular
interactions but might also include the eﬀect of secreted mol-
ecules. In particular, in encapsulated condition, hepatocytes
and MSC are distributed throughout the microcapsules
(Figure 6(a)); both improved microenvironment and para-
crine signaling through secreted molecules might contribute
to the increased viability and functionality of hepatocytes.
5. Conclusion
In conclusion, we performed high-yield porcine hepatocyte
isolations that allow obtaining high quantities of viable
hepatocytes. Further, we used a newly developed polymeric
biomaterial which allowed the maintenance of hepatocyte
viability, albumin secretion, and drug metabolic functions
up to 8 days. Furthermore, hepatocyte coencapsulation with
MSC increased and prolonged hepatocyte viability, suggest-
ing that cell-to-cell contact and paracrine eﬀects are beneﬁcial
for hepatocyte function and survival. This optimized protocol
for porcine hepatocyte isolation and microencapsulation can
50 휇m
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Figure 8: Distribution of porcine hepatocytes and human MSC in coculture. Cells were cultured for 2 days and then serum-starved to avoid
nonspeciﬁc staining. Immunoﬂuorescence was performed on cells after 3 days of culture. (a) Hepatocytes are stained for porcine albumin (in
red). (b) Coculture of hepatocytes and MSC. MSC are stained for human vimentin (in green). (c) Coculture of hepatocytes and MSC in a
higher magniﬁcation (×40). Images are representative of 2 independent pig hepatocyte isolations.
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now be used for further experimental cell transplantation
research in liver diseases to evaluate further the potential
of encapsulated hepatocytes for the treatment of acute liver
failure in humans.
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